Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in
treating patients with refractory solid tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania